Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in IgG4-Related Disease
2023-508290-81-00Phase 3Authorised
- Sponsor
- Horizon Therapeutics
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in IgG4-related disease (IgG4-RD) comparing Inebilizumab with Placebo (2 arms). Primary endpoint: Time to disease flare. Planned start Mar 2024; status: authorised.
02
Drugs
inebilizumab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on 2023-508290-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508290-81-00.